Pain Therapeutics stock plunges after company slams FDA for refusing to approve drug

Shares of Pain Therapeutics Inc. fell 18% Tuesday after the company released a statement railing against the U.S. Food and Drug Administration’s refusal to approve drug candidate Remoxy.